• Patient derived insights guiding pathway identification: datamining of disease tissues

  • Rational approach to target discovery and drug design: immune modulation via therapeutic antibodies

  • Focused on areas of high unmet medical need: rare disease, leukemia, autoimmunity and cancer

abcuro

the next generation of T cell targeted bio-therapeutics
Finding A Cure Starts with Patients
SCIENCE
TEAM
PIPELINE

HOW IT WORKS

We take a patient-centric approach to identify dysfunctional immune pathways, validate their role in disease and discover new therapies to modulate their function.

AT A GLANCE

Abcuro Founder Reports on the Role of KLRG1+ T cells in Inclusion Body Myositis

Posted by

Abcuro co-founder Steven A Greenberg, MD and his collaborators have published results of studies on clinical samples in inclusion body myositis (IBM), titled “Highly Differentiated Cytotoxic T Cells in Inclusion Body Myositis”. IBM is an autoimmune disease characterized by T cell infiltration and attack … Read More

Featured Post

Abcuro Founder Reports on the Role of KLRG1+ T cells in Primary Billiary Cholangitis

Posted by

Abcuro co-founder Steven A Greenberg, MD and his collaborators have published results of studies on clinical samples in primary biliary cholangitis (PBC), titled “Cytotoxic KLRG1 Expressing Lymphocytes Invade Portal Tracts in Primary Biliary Cholangitis”. PBC is an autoimmune disease characterized by T cell … Read More

Featured Post